HOME /Group 3

Group 3 – Materials in vitro

Research directions:  Cells and metabolomics for biomaterials research.

Group aims to improve the current understanding of the underlying molecular mechanisms of cell-material interactions with the main focus on metabolism. The Group will use this knowledge to develop biomaterials with desired immunomodulatory properties. Furthermore, Group aim to create in vitro based tools to predict patient response to biomaterial treatment.

Group leader: Dr.Kristaps Klavins

ResearchGate: https://www.researchgate.net/profile/Kristaps-Klavins
ORCID: https://orcid.org/0000-0001-9577-9990

In 2014 Kristaps Klavins obtained a Ph.D. from the University of Natural Resources and Life Sciences – BOKU, Vienna, Austria. After finishing his Ph.D., he joined the company "Biocrates Life Sciences AG" as a Senior Scientist at the Department of Research and Development. In 2017 Kristaps Klavins joined CeMM - Research Centre for Molecular Medicine of the Austrian Academy of Sciences as Deputy Head of Proteomics and Metabolomics Facility. He was responsible for setting up and managing the metabolomics facility. In 2020 he received a Marie Skłodowska-Curie Individual Fellowship and joined Rudolfs Cimdins Riga Biomaterials Innovations and Development Centre at Riga Technical University.

Fields of expertise: Metabolomics, lipidomics, liquid chromatography – mass spectrometry, in vitro material testing, analytical chemistry.

BBCE project´s main objective is to establish a joint Baltic Biomaterials Centre of Excellence for advanced biomaterials development based on the long-term strategic cooperation between AO Research Institute Davos, Switzerland (ARI) and Friedrich-Alexander University of Erlangen-Nuremberg, Germany (FAU) on the one hand and RTU RBIDC, LIOS, RSU and RSU IS on the other hand.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 857287